Top advances of the year: The status of chimeric antigen receptor T cells in neuro‐oncology
Abstract
Numerous major advances have been made in the past year regarding chimeric antigen receptor (CAR) T‐cell therapy in neuro‐oncology. Disialoganglioside GD2 CAR T cells, bivalent CAR T cells, and CARv3–engineered T cells expressing a T‐cell–engaging antibody molecule all show promise for diffuse midline glioma and glioblastoma.Keywords
This publication has 22 references indexed in Scilit:
- Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapyCell Stem Cell, 2024
- Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategiesBiomedicine & Pharmacotherapy, 2024
- Intraventricular CARv3-TEAM-E T Cells in Recurrent GlioblastomaNew England Journal of Medicine, 2024
- Therapeutic avenues for targeting treatment challenges of diffuse midline gliomasNeoplasia, 2023
- T cell exhaustion in malignant gliomasTrends in Cancer, 2023
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent GlioblastomaJAMA Oncology, 2020
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasNew England Journal of Medicine, 2017
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral gliomaProceedings of the National Academy of Sciences, 2012